German anti-infectives firm AiCuris partners to develop new class of Artilysin antimicrobials that rapidly burst bacterial cells and could have an improved resistance profile.

Cambridge Innovation Capital completes £150m fundraising to give it more firepower to reinforce Cambridge, UK’s pre-eminent status as Europe’s leading life sciences and tech hub.

The Japanese pharmaceutical companies will work with the Global Antibiotic Research and Development Partnership on screening targets for utility against WHO-listed priority pathogens. Avacta and LG Chem collaborate around the former’s Affimer technology.

Emerging Company Profile: Cyclenium Pharma spoke with Scrip about macrocyclic drug discovery, which covers the molecular space between traditional small molecules and large bio-molecules, to capture the pharmacological properties of larger peptides/proteins in metabolically stable small molecules and proven in a broad range of target classes.